Ispire Technology Inc. (ISPR) Market Cap
Ispire Technology Inc. has a market capitalization of $93.1M.
Financials based on reported quarter end 2025-12-31
Price: $1.63
▼ -0.09 (-4.97%)
Market Cap: 93.10M
NASDAQ · time unavailable
CEO: Tuanfang Liu
Sector: Consumer Defensive
Industry: Tobacco
IPO Date: 2023-04-04
Website: https://www.getispire.com
Ispire Technology Inc. (ISPR) - Company Information
Market Cap: 93.10M · Sector: Consumer Defensive
Ispire Technology Inc. manufactures e-cigarettes and cannabis vaping products. The company was founded in 2019 and is based in Los Angeles, California. Ispire Technology Inc. operates as a subsidiary of Pride Worldwide Investment Limited
Analyst Sentiment
Based on 1 ratings
Consensus Price Target
No data available
Price & Moving Averages
Related Companies in Consumer Defensive
SOLESENCE INC (SLSN)
Consumer Defensive
$0.09B
Mkt Cap
ZEVIA CLASS A (ZVIA)
Consumer Defensive
$0.09B
Mkt Cap
FITLIFE BRANDS INC (FTLF)
Consumer Defensive
$0.08B
Mkt Cap
HF FOODS GROUP INC (HFFG)
Consumer Defensive
$0.11B
Mkt Cap
HAIN CELESTIAL GROUP INC (HAIN)
Consumer Defensive
$0.07B
Mkt Cap
BEAUTY HEALTH COMPANY CLASS A CLAS (SKIN)
Consumer Defensive
$0.11B
Mkt Cap
Fundamentals Overview
📊 AI Financial Analysis
Powered by StockMarketInfo"ISPR reported revenue of $20.3M for the fiscal year ending December 31, 2025, with a net income loss of $6.6M, resulting in an EPS of -$0.12. The company faced negative operating cash flows of $3.97M and had total assets of $84.4M against total liabilities of $92.1M, leading to negative equity of $7.66M. The stock has experienced a significant decline in value, with a 1-year change of -43.61%. The company is currently not generating positive free cash flow and has not paid any dividends. This reflects ongoing operational challenges and highlights a need for structural improvements to return to profitability. The negative equity and high debt levels raise concerns regarding financial stability, indicating that shareholder returns may not improve in the near term unless substantial operational changes are made."
Revenue Growth
Modest revenue but no growth trend evident.
Profitability
Significant net income loss, indicating poor profitability.
Cash Flow Quality
Negative operating cash flow and free cash flow raises concerns.
Leverage & Balance Sheet
High liabilities relative to assets creating negative equity.
Shareholder Returns
No dividends paid and negative stock performance.
Analyst Sentiment & Valuation
Negative market changes and uncertainty in valuation.
Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.
Management frames Q2 2026 as an “inflection point,” citing lower net loss ($6.6M vs $8.0M), lower operating expenses ($10.3M vs $15.1M), and a large working-capital improvement (net accounts receivable $37.9M vs $47.0M). However, the quarter’s headline outcome is still a sharp contraction in performance: revenue fell to $20.3M from $41.8M and gross margin slipped to 17.1% from 18.5% due to product-mix changes tied to the customer pivot away from lower-value cannabis clients. In the Q&A, analyst pressure centered on real-world commercialization (Walgreens shelf dynamics; Charlie’s deal details). Management’s most concrete near-term numbers are iQTEC chip volumes (2–3M/month initially; up to 10M/month over 12 months) and timing (Charlie’s launch in 2–3 months; lift expected next quarter). Risks remain: international nicotine volume pressure from Chinese manufacturers and an April 1 China VAT change that could swing export flows, while US enforcement alone is not denting illicit demand.
Growth Catalysts
- iQTEC age-gating traction tied to FDA stance that age-gating is required to unlock approval for flavored e-cigarettes
- Charlie’s partnership expected to launch in 2-3 months; iQTEC chip volumes ramp starting next quarter (per management)
- Gmesh technology discussions with nicotine companies for potential licensing/partnership (update expected next month)
- Malaysian facility build-out on track; capacity increase to 80 production lines from current 6 lines, ramping in fiscal 2026
Business Development
- iQTEC partnership development deal with Charlie’s (consumer safety-oriented brand); operational chip targets shared
- Discussions with major tobacco players in the US; increased interest over prior three months after FDA position
- Regulatory engagement: FDA roundtable participation (Steve Casbella) and PMTA/component PMTA work (turn-in in May; FDA review expected in short order per management)
- Worked with regulators in UK/Europe and Southeast Asia/Middle East (no country names publicly disclosed under NDA, but UK mentioned publicly; two unnamed Southeast Asia countries and one Middle East country referenced)
Financial Highlights
- Revenue: $20.3M in Q2 2026 vs $41.8M in prior fiscal year period (strategic move away from lower value cannabis customers)
- Gross profit: $3.5M vs $7.7M; gross margin: 17.1% vs 18.5% (decline from product mix with fewer higher-margin products)
- Net loss: $6.6M vs $8.0M (improvement)
- Net accounts receivable: $37.9M as of 12/31/2025 vs $47.0M as of 06/30/2025
- Operating expenses: $10.3M vs $15.1M (for Q2 period)
- Operating cash burn: only $1.0M from April 2025 through end of calendar 2025
- Cash collected vs revenue: 116% in calendar 2025 vs 67% in calendar 2024
- Days sales outstanding improved by 8 days (2026 vs 2025 per management discussion)
- Tax/tariff-related: China VAT refund initiative end effective April 1; export facing additional 13% VAT due to policy change (management framed as a driver of export surge before deadline)
Capital Funding
- No explicit buyback/debt amounts disclosed in transcript
- Cash: $17.6M at 12/31/2025 vs $24.4M at 06/30/2025
- Net cash used in operating activity: $5.2M over six months to 12/31/2025 vs $0.4M provided over six months to 12/31/2024
- Net cash used in investing: $0.9M over first half of fiscal 2026 vs $1.1M used in prior year same period
- Net cash used in financing: $0.7M over six months to 12/31/2025 vs $0 utilization in prior comparable period (per CFO phrasing)
Strategy & Ops
- Consolidated customer base since late fiscal 2025 to prioritize higher-quality clients (higher value nicotine sector; shift away from cannabis and slower-paying clients)
- Improved working-capital discipline: shortened average payment terms and reduced days sales outstanding by 8 days vs prior period
- Cost reduction: operating cash burn limited to $1M from April 2025 through end of calendar 2025
- Manufacturing expansion: Malaysia facility build-out on track for fiscal 2026 ramp; capacity to 80 lines from 6 lines
Market Outlook
- US retail/shelf space: management expects potential acceleration once FDA authorizes flavored products; Walgreens viewed as not isolated
- iQTEC volume timing: Charlie’s initial chip volume expected at 2M-3M chips/month with goal up to 10M chips/month over 12 months; launch in next 2-3 months; no immediate lift expected in current quarter, results expected next quarter
- Regulatory timing: FDA component PMTA review expected 'in short order' (per management) after component PMTA turned in May
Risks & Headwinds
- Nicotine sector headwind internationally: e-cigarette volume declining due to pressure from Chinese manufacturers (management linked to China producers impacting the sector)
- Illicit market mitigation still not showing impact on demand: management stated US state enforcement and seizures/arrests 'barely put a dent' in illicit market demand side
- China export timing risk: VAT change effective April 1 expected to raise cost base and selling price; management expects spike may continue into current quarter with slowdown after April 1
- Technology adoption dependence: enforcement 'will be very, very ineffective' unless paired with a reliable age-gating solution (management emphasis on requirement for solution alongside enforcement)
Sentiment: MIXED
Note: This summary was synthesized by AI from the ISPR Q2 2026 (ended 12/31/2025) earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.